June 24, 2024
4 min watch
Save
VIDEO: Belantamab mafodotin’s ‘reemergence’ in treatment of multiple myeloma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video, Adam Cohen, MD, discussed findings from the DREAMM-7 and DREAMM-8 trials presented at ASCO Annual Meeting.
The trials combined belantamab mafodotin (Blenrep, GSK) with standard-of-care treatments in patients with relapsed/refractory multiple myeloma. Both trials met their primary endpoints.
“I think we’re looking at longer follow-ups, looking at survival,” Cohen, associate professor of medicine in hematology-oncology at Hospital of the University of Pennsylvania, said. “But I suspect that this may lead to the reemergence of these belantamab combinations as options for our patients.”
References:
- Mateos MV, et al. Abstract 7503. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
- Trudel S, et al. Abstract LBA105. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Cohen reports serving as a consultant for AstraZeneca, Bristol Myers Squibb, Genentech/Roche, GSK, Ichnos, iTeos, Janssen, Pfizer and Sanofi; receiving funding from Genentech/Roche, GSK, Janssen and Novartis; and having patents with Novartis.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.